GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Short Percentage of Float

Medivir AB (Medivir AB) Short Percentage of Float


View and export this data going back to . Start your Free Trial

What is Medivir AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Medivir AB's Short Percentage of Float

For the Biotechnology subindustry, Medivir AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivir AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Medivir AB's Short Percentage of Float falls into.


Medivir AB (Medivir AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Short Percentage of Float
Comparable Companies
OSTO:SYNACT OSTO:ACE XSAT:HAMLET B XSAT:CURAS OSTO:IVACC OSTO:MAGLE OSTO:CLBIO OSTO:NICA OSTO:IMMU OSTO:SANION OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
MVIR:Sweden MVR0:Germany
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Website
https://www.medivir.com
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.